You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
The St. Louis-based firm will use the funds to develop its colorectal cancer screening test, which measures eukaryotic RNA isolated from epithelial cells in stool.
Shanghai RAAS will become Grifols' exclusive distributor of plasma-derived products and transfusion diagnostic solutions in China.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
If, as some suspect, alien life forms are not DNA or nucleic acid based, a genome sequencer may be the tool to detecting them.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
The multi-analyte Zika virus assay was developed by a Luminex partner, GenArraytion, and is available now for research use only.
The isothermal technology from Cascade Biosystems performs about as well as qPCR and could be used in niche DNA detection applications.
The money from the Massachusetts Life Sciences Center will go toward developing a test that does not require laboratory instrumentation.
NEW YORK (GenomeWeb) – Nanosphere today reported a 38 percent jump in its first quarter revenues, but fell short of the consensus Wall Street estimates on the top and bottom lines.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.